Genscript Biotech Corporation (GNNSF)
R&D to Revenue
7.42%
Fiscal year · Period ending:

GNNSF R&D to Revenue
What is r&d to revenue?
R&D spending as percentage of revenue.
GNNSF r&d to revenue history
Annual fiscal periods. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D to Revenue |
|---|---|
| 7.4236% | |
| 9.048% | |
| 9.4021% | |
| 62.3457% | |
| 73.1287% | |
| 67.3925% | |
| 68.0517% | |
| 32.0652% | |
| 11.8278% | |
| 8.2512% | |
| 8.1987% | |
| 7.985% | |
| 10.0892% |
Frequently asked questions: GNNSF r&d to revenue
What is Genscript Biotech Corporation (GNNSF)'s current r&d to revenue?
Genscript Biotech Corporation (GNNSF)'s latest reported r&d to revenue (Fiscal year) is 7.42% as of Dec 31, 2025. R&D spending as percentage of revenue.
How much historical r&d to revenue data is available for GNNSF?
Stock Alarm Pro provides 13 dated annual fiscal periods observations for Genscript Biotech Corporation (GNNSF)'s r&d to revenue, allowing investors to analyze multi-year trends and cycle inflection points in Chart Studio.
How can I compare GNNSF's r&d to revenue to peers or set an alert?
You can open GNNSF's r&d to revenue in Stock Alarm Pro Chart Studio to overlay price and valuation multiples, or set real-time alerts on GNNSF delivered by push, email, or phone call.
Explore More
Explore 130+ historical metrics & ratios
Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance